SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-21-021763
Filing Date
2021-11-04
Accepted
2021-11-04 16:09:47
Documents
14
Period of Report
2021-11-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nltx-20211104.htm   iXBRL 8-K 32475
2 EX-99.1 ex-991xpressreleaseofneole.htm EX-99.1 65639
6 image_0a.jpg GRAPHIC 14539
  Complete submission text file 0001628280-21-021763.txt   262995

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nltx-20211104.xsd EX-101.SCH 1962
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nltx-20211104_lab.xml EX-101.LAB 24137
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nltx-20211104_pre.xml EX-101.PRE 12569
7 EXTRACTED XBRL INSTANCE DOCUMENT nltx-20211104_htm.xml XML 10591
Mailing Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102
Business Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102 206-732-2133
Neoleukin Therapeutics, Inc. (Filer) CIK: 0001404644 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36327 | Film No.: 211379999
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences